TY  - JOUR
AU  - Weller, J.
AU  - Schäfer, N.
AU  - Schaub, C.
AU  - Tzaridis, T.
AU  - Zeyen, T.
AU  - Schneider, M.
AU  - Potthoff, A. L.
AU  - Giordano, F. A.
AU  - Steinbach, J. P.
AU  - Zeiner, P. S.
AU  - Kowalski, T.
AU  - Sabel, M.
AU  - Hau, P.
AU  - Krex, D.
AU  - Grauer, O.
AU  - Goldbrunner, R.
AU  - Schnell, O.
AU  - Tabatabai, Ghazaleh
AU  - Ringel, F.
AU  - Schmidt-Graf, F.
AU  - Brehmer, S.
AU  - Tonn, J. C.
AU  - Bullinger, L.
AU  - Vajkoczy, P.
AU  - Glas, Martin
AU  - Vatter, H.
AU  - Herrlinger, U.
AU  - Seidel, C.
TI  - Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial.
JO  - Journal of neuro-oncology
VL  - 161
IS  - 1
SN  - 0167-594x
CY  - Dordrecht [u.a.]
PB  - Springer Science + Business Media B.V
M1  - DKFZ-2023-00044
SP  - 147-153
PY  - 2023
N1  - 2023 Jan;161(1):147-153
AB  - In the randomized phase III trial CeTeG/NOA-09, temozolomide (TMZ)/lomustine (CCNU) combination therapy was superior to TMZ in newly diagnosed MGMT methylated glioblastoma, albeit reporting more frequent hematotoxicity. Here, we analyze high grade hematotoxicity and its prognostic relevance in the trial population.Descriptive and comparative analysis of hematotoxicity adverse events ≥ grade 3 (HAE) according to the Common Terminology of Clinical Adverse Events, version 4.0 was performed. The association of HAE with survival was assessed in a landmark analysis. Logistic regression analysis was performed to predict HAE during the concomitant phase of chemotherapy.HAE occurred in 36.4
KW  - Glioblastoma (Other)
KW  - Hematotoxicity (Other)
KW  - Lomustine (Other)
KW  - MGMT (Other)
KW  - Temozolomide (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:36609807
DO  - DOI:10.1007/s11060-022-04203-4
UR  - https://inrepo02.dkfz.de/record/186675
ER  -